| All Releases |
|---|
 |
Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
Jun 22, 2009
|
12.1 KB
|
| |
SAN DIEGO, June 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that Scott Byrd has joined the company as Senior Vice President and Chief Commercial Officer. Mr. Byrd will report directly to Ted Schroeder, President and Chief Executive Officer, and his responsibilities will in...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
Jun 4, 2009
|
9.8 KB
|
| |
SAN DIEGO, June 4, 2009 /PRNewswire via COMTEX News Network/ -- SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's P...
|
|
|
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
May 14, 2009
|
13.9 KB
|
| |
SAN DIEGO, May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for the treatment of acute pai...
|
|
|
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
May 7, 2009
|
16.1 KB
|
| |
SAN DIEGO, May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, ...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
May 5, 2009
|
10.0 KB
|
| |
SAN DIEGO, May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
Apr 30, 2009
|
9.6 KB
|
| |
SAN DIEGO, April 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 3...
|
|
|
Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Apr 27, 2009
|
10.6 KB
|
| |
SAN DIEGO, April 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that data from clinical trials of its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 34th A...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
Mar 26, 2009
|
9.8 KB
|
| |
SAN DIEGO, March 26, 2009 /PRNewswire via COMTEX News Network/ -- SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company...
|
|
|
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results and Provides Corporate and Clinical Updates
Mar 12, 2009
|
21.8 KB
|
| |
SAN DIEGO, March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the fourth quarter and year end...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Cowen & Company's 29th Annual Health Care Conference in Boston on March 16, 2009
Mar 9, 2009
|
9.9 KB
|
| |
SAN DIEGO, March 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroed...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
Mar 5, 2009
|
10.2 KB
|
| |
SAN DIEGO, March 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year...
|
|
|
Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
Feb 19, 2009
|
11.6 KB
|
| |
SAN DIEGO, Feb 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it completed its previously announced private placement of approximately 12 million shares of the Company's common stock at a price of $7.13 per share and five-year warrants to purchase up to approximately 6 mi...
|
|
|
Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
Feb 17, 2009
|
11.7 KB
|
| |
SAN DIEGO, Feb 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has entered into an agreement to issue and sell in a private placement approximately 12 million shares of the Company's common stock and warrants to purchase up to approximately 6 million additional shares o...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
Feb 10, 2009
|
9.9 KB
|
| |
SAN DIEGO, Feb 10, 2009 /PRNewswire via COMTEX News Network/ -- SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's ...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
Feb 4, 2009
|
9.8 KB
|
| |
SAN DIEGO, Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Dec 17, 2008
|
14.8 KB
|
| |
SAN DIEGO, Dec 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc.
(Nasdaq: CADX) today announced positive topline results from Study 304, a
Phase III clinical trial of Acetavance(TM), the company's intravenous
formulation of acetaminophen, for the treatment of acute pain following
abdominal laparoscopic sur...
|
|
|
Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
Nov 6, 2008
|
18.4 KB
|
| |
SAN DIEGO, Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the third quarter and nine months...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Oct 29, 2008
|
10.4 KB
|
| |
SAN DIEGO, Oct 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter financial resul...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
Oct 21, 2008
|
10.1 KB
|
| |
SAN DIEGO, Oct 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
Sep 29, 2008
|
10.2 KB
|
| |
SAN DIEGO, Sept 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroed...
|
|
|
